ERBB2 and non-small cell lung carcinoma: In addition, the DESTINY-Lung02 trial validated the efficacy and safety of T-DXd in ERBB2-mutated NSCLC, although the dosage appeared to influence the response and safety, including the occurrence of drug-related ILD.